Adding immunotherapy to platinum-gemcitabine chemotherapy can improve outcomes in patients with advanced urothelial carcinoma, but that may depend on the platinum agent used, data suggest.

During the first decade of the Affordable Care Act (ACA), survival and mortality increased among young adults with cancer who were eligible for dependent care e ...

Safety results and AE management approaches for talquetamab were reported by oncology nurses practicing at study sites participating in the MonumenTAL-1 studies.

Recently, it has been demonstrated that in B-ALL, distinct developmental states are associated with genomic alterations and clinical characteristics.

Researchers found that patients diagnosed with HCC during 2013-2019 were less likely to die from HCC or from any cause than patients who were diagnosed during 2006-2012.

In the past decade, there have been significant advancements in targeted antibody-based immunotherapies for managing r/r ...

A liver-first treatment approach in primary and colorectal liver metastases (CRLM) is associated with worse recurrence-free survival (RFS) than primary-first or simultaneous treatment approaches, ...

Patients who achieved a pathologic complete response after neoadjuvant therapy had better survival outcomes than patients who received adjuvant therapy.

Ovarian cancer detected with specificity >99 percent and sensitivity ranging from 69 to 100 percent depending on stage.

Treatment with cediranib or cediranib plus olaparib is not superior to standard of care (SOC) in patients with platinum-resistant or -refractory epithelial ovarian cancer, according to results from a ...

Researchers sought to determine factors associated with mortality for patients with AML and hyperleukocytosis.

Survey results suggest that cancer patients want financial toxicity screening to occur early, but screening preferences and practices vary.